Bravelle Market Report 2026

Bravelle Market Overview

• The Bravelle market growth in the historic period has been driven by increasing infertility rates, success of ivf technologies • Market expansion is supported by growth in fertility tourism, rising acceptance of assisted reproduction • Growth Driver: The Rising Infertility Burden Fueling The Growth Of The Market Due To Growing Demand For Reproductive Assistance • North America was the largest region in 2025.

What Is Covered Under Bravelle Market?

Bravelle is a highly purified human follicle-stimulating hormone (FSH) treatment used in fertility therapies, particularly for women undergoing in vitro fertilization (IVF). It helps stimulate the ovaries to produce multiple eggs, crucial for successful IVF procedures, and is often prescribed to women who have difficulty producing eggs on their own. It is commonly used in conjunction with other fertility medications to enhance the chances of pregnancy. The main types of bravelle market are fresh in vitro fertilization (IVF) cycle, thawed in vitro fertilization (IVF) cycle, and donor egg in vitro fertilization (IVF) cycle. A fresh IVF cycle involves retrieving eggs from a woman's ovaries, fertilizing them in the laboratory with sperm, and transferring the resulting embryos into the uterus. The various techniques involved are in vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo transfer (FET), and other techniques. The multiple applications involved are human reproduction, and research and reproductive toxicology and are used by various end users such as fertility clinics, hospitals, surgical centers, and clinical research institutes.

What Is The Bravelle Market Growth Forecast?

The growth in the forecast period can be attributed to growth in fertility tourism, rising acceptance of assisted reproduction, technological advances in ivf, expansion of fertility clinics in emerging markets, improved treatment success rates. Major trends in the forecast period include rising use of hormonal stimulation in ivf, growth in assisted reproductive procedures, increased demand for purified fsh therapies, expansion of fertility treatment centers, improved ovarian stimulation protocols.

Global Bravelle Market Segmentation

1) By Type: Fresh In vitro fertilization (IVF) Cycle, Thawed In vitro fertilization (IVF) Cycle, Donor Egg In vitro fertilization (IVF) Cycle 2) By Technique: In Vitro Fertilization (IVF), Artificial Insemination (AI-IUI), Frozen Embryo Transfer (FET), Other Techniques 3) By Application: Human Reproduction, Research And Reproductive Toxicology 4) By End User: Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes

What Are The Drivers Of The Bravelle Market?

The increasing infertility rates are expected to propel the growth of the bravelle market going forward. Infertility refers to the inability to conceive after a year or more of regular unprotected intercourse or to sustain a pregnancy to term. The rise in infertility rates is largely driven by delayed childbearing as fertility naturally declines with age, reducing the chances of conception. Bravelle helps address infertility by stimulating the ovaries to produce multiple eggs, increasing the chances of successful fertilization and pregnancy, particularly in women with ovulatory disorders or those undergoing assisted reproductive techniques such as IVF. For instance, in May 2025, according to the Office for National Statistics (ONS), a UK-based government department, the total fertility rate (TFR) in England and Wales fell from 1.44 children per woman in 2023 to 1.41 in 2024, marking a 2.1% decline, reflecting a rise in infertility rates. Therefore, the increasing infertility rates are driving the growth of the Bravelle industry. The growing demand for personalized medicine is expected to drive the expansion of the market going forward. Personalized medicine refers to tailoring medical treatment to individual characteristics, such as genetics, lifestyle, and environment, to enhance treatment effectiveness. The rise in demand for personalized medicine is influenced by factors such as advancements in genomics, an increasing focus on precision healthcare, and the growing awareness of individualized treatment benefits. Bravelle, a recombinant form of follicle-stimulating hormone (FSH), personalizes treatment by stimulating ovarian follicle growth in women undergoing fertility therapy, enabling customized protocols that adjust to individual responses for optimal egg production and increased chances of pregnancy success. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for personalized medicine is driving the growth of bravelle industry.

Key Players In The Global Bravelle Market

Major companies operating in the bravelle market are Ferring Pharmaceuticals

What Are Latest Mergers And Acquisitions In The Bravelle Market?

In April 2023, Ferring International Center S.A., a Switzerland-based biopharmaceutical company, that specializes in providing bravelle medication, partnered with BII Holdings A/S. The partnership aims to accelerate innovation in women’s health by supporting early-stage start-ups and projects in reproductive medicine, addressing the underinvestment in female-specific healthcare conditions. BII Holdings A/S is a Denmark-based biotechnology startup company that specializes in providing innovative solutions and services in the field of life sciences and biotechnology.

Regional Insights

North America was the largest region in the bravelle market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Bravelle Market?

The bravelle market consists of sales of bravelle 75 iu injection, bravelle 100 iu injection, and bravelle urofollitropin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bravelle Market Report 2026?

The bravelle market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bravelle industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.